MRRS adds "Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 – Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Alzheimer’s Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first appear in patients in their mid-sixties, with symptoms appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.

Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerably high at 559. The majority of the pipeline products are novel drugs, with a total of seven repositioned and five generic drugs. This shows advancement in the progression of the different molecules being developed as therapeutic agents within the AD pipeline.

Table of Contents
1 Table of Contents 4
2 Introduction 9
2.1 Disease Introduction 9
2.2 Epidemiology 9
2.3 Symptoms 10
2.4 Etiology 12
2.5 Pathophysiology 12
2.6 Disease Stages 13
2.7 Diagnosis 14
2.8 Prognosis 17
2.9 Treatment 18
2.9.1 Treatment Algorithm 18
2.9.2 Mild-to-Moderate AD 20
2.9.3 Moderate-to-Severe AD 21
3 Marketed Products 22
3.1 Aricept (donepezil) - Eisai 22
3.2 Exelon (rivastigimine) - Novartis 22
3.3 Razadyne (galanatamine) - Janssen 23
3.4 Namenda/Ebixa/Axura/Abixa (memantine), Merz Pharma/Lundbeck/Forest/Daiichi Sankyo 23
3.5 Cognex (tacrine) - Shiniogi 24
3.6 Namzaric (memantine ER + donepezil), Actavis-Adamas 24
4 Heat Map - Marketed Products Overview 25
5 Pipeline Product Developments 26
5.1 The Pipeline Development Landscape 26
5.2 Mechanisms of Action in the Pipeline 27
5.3 Clinical Trials 31
5.3.1 Failure Rate 31
5.3.2 Clinical Trial Duration 32
5.3.3 Clinical Trial Size 34
5.3.4 Competitive Clinical Trials Metric Analysis 38......

List of Tables and Figures 
Table 1: Alzheimer’s Disease Therapeutics Market, Symptoms of Alzheimer’s Disease at Different Stages of Disease 11
Table 2: Alzheimer’s Disease Therapeutics Market, Symptoms of Mild Cognitive Impairment 11
Table 3: Alzheimer’s Disease Therapeutics Market, Global Deterioration Scale for Alzheimer’s Disease 14
Table 4: Alzheimer’s Disease Therapeutics Market, Mini-Mental State Exam 15
Table 5: Alzheimer’s Disease Therapeutics Market, Alzheimer’s Disease Assessment Scale Cognitive Subscale 16
Table 6: Alzheimer’s Disease Therapeutics Market, Mild Cognitive Impairment Diagnosis Guidelines Table 7: Management of AD Symptoms 20
Table 8: AD Market, Global, Pipeline Products, Discovery, 2016 87
Table 9: AD Market, Global, Pipeline Products, Preclinical, 2016 96
Table 10: AD Market, Global, Pipeline Products, Phase I, 2016 116
Table 11: AD Market, Global, Pipeline Products, Phase II, 2016 119
Table 12: AD Market, Global, Pipeline Products, Phase III, 2016 122
Table 13: MCI Market, Global, Market Forecast, 2014-2021 124
Figure 1: Alzheimer’s Disease Therapeutics Market, Treatment Algorithm of Alzheimer’s Disease 19
Figure 2: Alzheimer’s Disease Therapeutics Market, Heat Map for Marketed Products 25
Figure 3: Alzheimer’s Disease Therapeutics Market, Overall Pipeline 27
Figure 4: Alzheimer’s Disease Therapeutics Market, Pipeline by Mechanism of Action (%) 30
Figure 5: Alzheimer’s Disease Therapeutics Market, Clinical Trial Failure Rates by Phase (%) 31
Figure 6: Alzheimer’s Disease Therapeutics Market, Clinical Trial Failure Rates by Mechanism of Action, (%) 32
Figure 7: Alzheimer’s Disease Therapeutics Market, Clinical Trial Duration by Molecule Type (months) Figure 8: Alzheimer’s Disease Therapeutics Market, Clinical Trial Duration by Mechanism of Action (months) 34
Figure 9: Alzheimer’s Disease Therapeutics Market, Clinical Trial Size per Product by Molecule Type (participants) 35
Figure 10: Alzheimer’s Disease Therapeutics Market, Clinical Trial Size per Product by Mechanism of Action (participants) 36.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/alzheimers-disease-therapeutics-in-major-developed-markets-to-2021-aging-population-and-improved-disease-understanding-increase-demand-for-disease-modifying-agents

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/